clinical trial · NCT07536269
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Congenital Adrenal HyperplasiaCrinecerfont
brief summary
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
started
Apr 1, 2026
primary completion
Mar 1, 2028
completion
Mar 1, 2028
last updated
Apr 17, 2026
official title
A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol